mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

mTOR inhibition by TAK‐228 is effective against growth, survival and angiogenesis in preclinical retinoblastoma models

Published:2022-02 Issue:1 Volume:10 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacology Res & Perspec

Author:

Tang Lanlan¹,Fu Yu¹,Song Jiarun¹,Hu Taibing²,Li Kun¹,Li Zhi³^ORCID

Affiliation:

1. Department of Ophthalmology Wuchang Hospital Affiliated to Wuhan University of Science and Technology Wuhan Hubei China

2. Department of Orthopaedic Wuchang Hospital Affiliated to Wuhan University of Science and Technology Wuhan Hubei China

3. Department of Ophthalmology Zhongnan Hospital of Wuhan University Wuhan Hubei China

Funder

Health and Family Planning Commission of Hubei Province

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.930

Reference31 articles.

1. Targeting mTOR and Metabolism in Cancer: Lessons and Innovations

2. The role of mTOR in age-related diseases

3. Tumor angiogenesis and anti‐angiogenic gene therapy for cancer;Li T;Oncol Lett,2018

4. Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

5. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. mTOR signalling pathway in stem cell bioactivities and angiogenesis potential;Cell Proliferation;2023-05-08

2. Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario;Pharmaceutics;2023-02-16

3. 3,4-Diaminopyrazolo[3,4-d]pyrimidines: a new three-component microwave-assisted synthesis and anti-leukemic properties;Organic & Biomolecular Chemistry;2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3